Demographic Data
Up to November 2016, a total of 3598 courses of biologics were used in 2265 patients (1323 women and 942 men) with various rheumatic diseases. The mean age of these patients at the commencement of biological treatment was 46.9 years (range 7-89 years). More than half of the patients suffered from rheumatoid arthritis while the others were mainly patients suffering from ankylosing spondylitis and psoriatic arthritis. Other indications of the biologics are shown in Table 1 . The longest duration of therapy was 156 months. 
Infection Requiring Hospitalization
There were 114 episodes of infective complications requiring hospitalization. More than 60% of them (i.e., 70 cases) occurred during the first 12 months of biological therapy.
Tuberculosis
A total of 58 cases of TB were reported: 31 related to Infliximab, 12 related to Etanercept, 8 related to Adalimumab, 4 related to Golimumab and 3 related to Tocilizumab. Nearly 40% of the cases (i.e., 22 cases) occurred in the first 6 months of treatment. There were 442 abnormal CXRs before treatment and isoniazid chemoprophylaxis was given to 750 patients with latent TB as defined by either one: a positive MT2 (≥10mm induration) or positive in IGRA test.
